This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Titan Pharmaceuticals, Inc.
Drug Names(s): 3,5-diiodothyroproprionic acid
Description: DITPA is an analogue of naturally occurring thyroid hormone (T3) that has been specifically designed to improve cardiac performance with a lower potential for tachycardia in CHF patients. Although structurally similar to T3, DITPA has a propionic acid side chain and lacks an iodine at the 3' position of the outer phenolic ring. While DITPA binds to the same thyroid hormone receptors as T3, binding affinities are significantly less, suggesting partial agonistic actions.
In addition to affecting the contractility of the heart, other properties that DITPA appears to share with thyroid hormone are the stimulation new blood vessel formation (angiogenesis) and an effect on lipid metabolism.
Deal Structure: In October 2003, through the acquisition of Developmental Therapeutics (DTI), Titan acquired an exclusive worldwide license to an issued U.S. patent and pending international patent applications covering DITPA. Under this license agreement, Titan made an initial stock payment and a cash payment to The University ofArizona, the licensor of the technology, and will also make an additional payment of common stock upon the achievement of positive pivotal study results or certain other substantial milestones within five years. Also under this agreement, Titan is required to make royalty payments to the licensor based on net sales of products and processes incorporating the licensed technology, subject to minimum annual amounts commencing in the first year following the commercial sale of the product. In addition, Titan is required to make milestone payments to the licensor upon the achievement of certain clinical or regulatory milestones.
Additional information available to subscribers only: